ERBB2 and breast carcinoma: We therefore tested whether the elevated ER stress induction by Bortezomib could have a synergistic or additive effect with Trastuzumab against ErbB2-overexpressing, low CHIP-expressing, BT474 and SKBR3 breast cancer cells.